# Task 03/13: Product Development Plans for Vaccines

> **NIH NIH N01** · SRI INTERNATIONAL · 2020 · $95,183

## Abstract

The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models. This contract also provides testing of vaccines for safety and immunogenicity, to include humoral and cellular immunity, in small animals as well as non-human primates, under GLP where appropriate. In addition, it can perform testing of therapeutics for safety and pharmacology, in small animals as well as non-human primates, under GLP where appropriate.

## Key facts

- **NIH application ID:** 10162359
- **Project number:** N01AI40005-P00015-9999-2
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** LAURENCE LEMIALE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $95,183
- **Award type:** —
- **Project period:** 2003-11-20 → 2012-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10162359

## Citation

> US National Institutes of Health, RePORTER application 10162359, Task 03/13: Product Development Plans for Vaccines (N01AI40005-P00015-9999-2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10162359. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*